Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide.

Autor: Mathur A; Department Haematology Aberdeen Royal Infirmary Foresterhill Health Campus Aberdeen UK., Edman J; School of Medicine Medical Sciences and Nutrition Aberdeen University Aberdeen UK., Liang L; National University Health System National University Hospital Singapore Singapore., Scott NW; Institute of Applied Health Sciences University of Aberdeen, Polwarth Building, Foresterhill Aberdeen UK., Watson HG; Department Haematology Aberdeen Royal Infirmary Foresterhill Health Campus Aberdeen UK.; School of Medicine Medical Sciences and Nutrition Aberdeen University Aberdeen UK.
Jazyk: angličtina
Zdroj: EJHaem [EJHaem] 2022 Sep 02; Vol. 3 (4), pp. 1305-1309. Date of Electronic Publication: 2022 Sep 02 (Print Publication: 2022).
DOI: 10.1002/jha2.551
Abstrakt: Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in MPN patients. In this retrospective observational study, we report a single-centre experience of 324 HC-treated MPN patients with long-term follow-up, compared to 47 MPN patients not on HC. Thirty-three patients (10.2%) (HC) versus one patient (2.1%) (no HC) developed skin tumours during follow-up (Hazard ratios [HR] 5.70, 95% confidence intervals 0.66-48.09, p  = 0.112). However, male gender, age at MPN diagnosis, type of MPN (polycythaemia rubra vera) and previous history of skin cancer were prognostic variables associated with development of skin cancer.
Competing Interests: The authors declare they have no conflicts of interest.
(© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: